Motif Bio Investor & Analyst Day

New York, September 20, 2017

Motif Bio Investor & Analyst Day
Wednesday, September 20th in New York

Presentations start at 8:00 am EDT (registration/breakfast at 7:30 am EDT)

Convene
780 Third Avenue, Concourse Level 2
New York, NY 10017

 

A Discussion with Management & Key Opinion Leaders

Agenda:

Introduction

Graham G Lumsden, BVM&s, MRCVS, Chief Executive Officer & Executive Director, Motif Bio

Iclaprim Overview & REVIVE-1 Results

David Huang, Ph.D., M.D., Chief Medical Officer, Motif Bio

William D. O'Riordan, M.D., FACEP, Chief Medical Officer, eStudySite

HABP Treatment Considerations & Unmet Needs

Thomas M. File, Jr., M.D., M.Sc., MACP, FIDSA, FCCP, Chair, Infectious DIsease Division, Summa Health

Summary 

Graham G. Lumsden, BVM&S, MRCVS, MCIM, Chief Executive Officer & Executive Director, Motif Bio

Challenges in Managing Hospitalized ABSSSI Patients with Renal Impairment

Francis Natale, PharmD, Director of Pharmacy, Methodist Hospital Division, Thomas Jefferson University Hospitals

Thomas Holland, M.D., MSc-GH, Duke University School of Medicine & Clinical Research Institute

Economic Burden of High Risk Hospitalized ABSSSI Patients

Tom Lodise, Ph.D., PharmD, Albany College of Pharmacy & Health Sciences

Commercial Market Opportunity

Lynda Berne, M.S., M.B.A., Commercial Head, Motif Bio

Q&A

All

Summary 

Graham G. Lumsden, BVM&S, MRCVS, MCIM, Chief Executive Officer & Executive Director, Motif Bio

 

Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Motif Bio plc MTFB $116 MM MCap
Ph 3 antibi­ot­ic com­pany (pos­i­tive da­ta an­nounced; NDA fil­ing 1Q18) fo­cused on life-threat­en­ing in­fec­tions caused by mul­ti-drug re­sis­tant bac­te­ria. To­p­line re­sults with Iclaprim in pa­tients with acute... [more in­for­ma­tion]